Valuation: Sernova

Market Cap 3.78Cr 2.72Cr 2.35Cr 2.21Cr 2.01Cr 260.47Cr 3.83Cr 26Cr 10Cr 130.27Cr 10Cr 9.99Cr 433.92Cr P/E 2026 *
-3.5x
P/E 2027 * -2.63x
Enterprise Value 3.78Cr 2.72Cr 2.35Cr 2.21Cr 2.01Cr 260.47Cr 3.83Cr 26Cr 10Cr 130.27Cr 10Cr 9.99Cr 433.92Cr EV / Sales 2026 *
-
EV / Sales 2027 * 7.55x
Free-Float
86.84%
Yield 2026 *
-
Yield 2027 * -
1 week-9.09%
Current month-9.09%
1 month-13.04%
3 months-35.48%
6 months-25.93%
Current year-23.08%
1 week 0.1
Extreme 0.1
0.12
1 month 0.1
Extreme 0.1
0.12
3 years 0.1
Extreme 0.1
0.91
5 years 0.1
Extreme 0.1
2.22
10 years 0.1
Extreme 0.095
2.87
Manager TitleAgeSince
Chief Executive Officer 58 12/08/2024
Director of Finance/CFO 60 11/10/2024
Investor Relations Contact - 11/10/2024
Director TitleAgeSince
Director/Board Member 60 19/04/2012
Director/Board Member - 24/04/2023
Director/Board Member - 01/09/2024
Change 5-day change 1-year change 3-year change Capi.($)
+5.00%-9.09%-50.00%-87.50% 2.72Cr
-0.09%-4.18%-13.23%+19.23% 13TCr
+2.07%+0.45%-17.47%+2.59% 1.24TCr
-0.79%+1.50%+104.93%+155.37% 1.09TCr
-2.05%-7.70%-46.42%-68.85% 444.87Cr
+0.11%-0.45%-25.69%+42.67% 266.5Cr
-0.70%-3.11%-21.90%-14.22% 166.37Cr
+0.28%-3.92%-34.62%-72.80% 165.43Cr
-1.01%-3.26%-35.17%-36.93% 163.68Cr
Average -0.09%-2.61%-15.51%-6.71% 2.03TCr
Weighted average by Cap. +0.94%-3.47%-7.25%+23.23%

Financials

2026 *2027 *
Net sales - 50L 35.99L 31.09L 29.25L 26.58L 34Cr 50.73L 3.43Cr 1.34Cr 17Cr 1.35Cr 1.32Cr 57Cr
Net income -1.28Cr -92.34L -79.75L -75.04L -68.2L -88Cr -1.3Cr -8.8Cr -3.45Cr -44Cr -3.47Cr -3.39Cr -147.39Cr -1.98Cr -1.42Cr -1.23Cr -1.16Cr -1.05Cr -136.37Cr -2.01Cr -14Cr -5.32Cr -68Cr -5.34Cr -5.23Cr -227.19Cr
Net Debt - -
Logo Sernova
Sernova Biotherapeutics Inc. is a Canada-based clinical-stage company, which is focused on developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem cell-derived cell therapies to create bio-hybrid organs to treat chronic diseases. A bio-hybrid organ is comprised of non-biomaterials, such as the Cell Pouch, integrated with living tissues to restore or enhance the function of a compromised organ. This approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on type 1 diabetes (T1D) and thyroid disorders. Cell Pouch is a bio-hybrid organ which is surgically implanted beneath the skin of the abdomen.
Employees
-
Date Price Change
18/26/18 CA$0.1050 +5.00%
17/26/17 CA$0.1000 -9.09%
14/26/14 CA$0.1100 0.00%
13/26/13 CA$0.1100 -4.35%
12/26/12 CA$0.1150 +4.55%
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.1000CAD
Average target price
0.4500CAD
Spread / Average Target
+350.00%

Quarterly revenue - Rate of surprise